N

    Nkarta Inc (NKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.71
    -0.05 (-1.81%)

    Market Cap: $194.10M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(12/25)
    Avg Surprise
    -1.08%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.39
    Range$-0.46 - $-0.34
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.41-6.0%
    60d ago$-0.39+0.4%
    30d ago$-0.37+4.3%
    7d ago$-0.37+4.3%
    Current$-0.39
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.59
    Range$-0.74 - $-0.49
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.59---
    Sep 26EST
    		-$-0.39---
    Jun 26
    Reported Aug 10
    		$-0.54$-0.39-38.46%Miss-74.2%
    Mar 26
    Reported May 12
    		$-0.37$-0.36-2.68%Miss+12.8%
    Dec 25
    Reported Mar 25
    		$-0.37$-0.29-27.59%Miss-5.7%
    Sep 25
    Reported Nov 10
    		$-0.29$-0.30+3.33%Beat+25.6%
    Jun 25
    Reported Aug 12
    		$-0.31$-0.35+11.43%Beat+8.8%
    Mar 25
    Reported May 14
    		$-0.43$-0.45+4.44%Beat+25.9%
    Dec 24
    Reported Mar 26
    		$-0.35$-0.40+12.50%Beat+38.6%
    Sep 24
    Reported Nov 7
    		$-0.39$-0.36-8.33%Miss+25.0%
    Jun 24
    Reported Aug 13
    		$-0.34$-0.51+33.33%Beat+50.0%
    Mar 24
    Reported May 9
    		$-0.58$-0.56-3.57%Miss+7.9%
    Dec 23
    Reported Mar 21
    		$-0.57$-0.59+3.39%Beat+14.9%
    Sep 23
    Reported Nov 9
    		$-0.52$-0.65+20.00%Beat+10.3%
    Jun 23
    Reported Aug 10
    		$-0.68$-0.68+0.00%Beat-11.5%
    Mar 23
    Reported May 11
    		$-0.63$-0.70+10.00%Beat+20.3%
    Dec 22
    Reported Mar 16
    		$-0.67$-0.64-4.69%Miss+2.9%
    Sep 22
    Reported Nov 9
    		$-0.58$-0.62+6.45%Beat+14.7%
    Jun 22
    Reported Aug 11
    		$-0.61$-0.59-3.39%Miss+7.6%
    Mar 22
    Reported May 12
    		$-0.79$-0.72-9.72%Miss-33.9%
    Dec 21
    Reported Mar 17
    		$-0.69$-0.90+23.33%Beat-25.5%
    Sep 21
    Reported Nov 10
    		$-0.68$-0.66-3.03%Miss-54.5%
    Jun 21
    Reported Aug 12
    		$-0.66$-0.59-11.86%Miss+89.1%
    Mar 21
    Reported May 13
    		$-0.59$-0.52-13.46%Miss+14.5%
    Dec 20
    Reported Mar 25
    		$-0.55$-0.44-25.00%Miss-
    Sep 20
    Reported Nov 12
    		$-0.44$-0.39-12.82%Miss-
    Jun 20
    Reported Jul 13
    		$-6.08$-6.71+9.39%Beat-
    Mar 20
    Reported Apr 20
    		$-0.69$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.72EV/EBITDA0.95x
    Price/FCF-2.15xFCF Yield-46.52%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-38.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio7.98xQuick Ratio7.98x
    Trading Statistics
    Beta0.94Avg Volume541.20K
    52-Week High$3.7252-Week Low$1.70

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.62
    SMA 20$2.48
    SMA 50$2.61
    SMA 200$2.42
    EMA 10$2.63
    EMA 20$2.55
    EMA 50$2.57
    EMA 200$2.47

    MACD

    Line: 0.06Signal: 0.01Hist: 0.05

    ADX

    ADX: 20.7+DI: 28.0-DI: 14.2

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down16.0
    PSAR$2.59

    Bollinger Bands

    Upper Band$2.83
    Lower Band$2.13
    %B Position2838%(Upper)
    Band Width0.82

    RSI (14-Day)

    Neutral
    57.6

    Momentum Oscillators

    Stoch %K91.2
    Stoch %D89.0
    Williams %R-14.6
    ROC (10d)11.5%
    Momentum0.28
    CCI (20d)106.1
    MFI (14d)61.1

    Volatility Measures

    ATR (14d)$0.16(5.8%)
    StdDev (20d)0.18
    Hist Vol60.7%(High)

    Volume Flow

    VWAP$2.70
    OBV40.7M
    AD Line3.6M
    CMF (20d)0.237

    Volume Metrics

    Avg Vol (20d)537.8K
    Vol Ratio0.9x
    VWMA (20d)$2.47

    Pivot Points

    R3$2.90
    R2$2.84
    R1$2.80
    Pivot Point$2.75
    S1$2.71
    S2$2.65
    S3$2.61

    Advanced Oscillators

    TSI9.73
    Ultimate Osc62.4
    KST47.61

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$9.03M$0$0$0$10.54M$0
    Cost of Revenue$0$0$2.26M$0$0$0$4.52M$0$0$0$2.25M$0
    Gross Profit$0$0$-2,257,000$0$0$0$4.52M$0$0$0$8.29M$0
    Operating Expenses$43.13M$30.88M$30.96M$27.29M$27.19M$36.56M$30.92M$33.79M$30.71M$32.76M$31.18M$29.29M
    R&D$29.05M$24.99M$25.28M$20.20M$20.78M$24.17M$23.13M$25.25M$23.13M$25.24M$23.32M$22.19M
    SG&A$14.08M$5.89M$5.68M$7.09M$6.41M$12.39M$7.80M$8.54M$7.58M$7.53M$7.86M$7.10M
    Operating Income$-43,128,000$-30,876,000$-30,961,000$-27,286,000$-27,186,000$-36,564,000$-30,923,000$-33,794,000$-30,715,000$-32,762,000$-31,185,000$-29,294,000
    Interest Income$2.54M$2.84M$3.30M$3.85M$3.97M$4.38M$4.89M$5.45M$5.72M$3.25M$3.46M$3.62M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-40,368,000$-27,832,000$-27,409,000$-21,715,000$-22,977,000$-31,983,000$-25,935,000$-28,344,000$-24,993,000$-29,518,000$-27,754,000$-25,645,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-40,368,000$-27,832,000$-27,409,000$-21,715,000$-22,977,000$-31,983,000$-25,935,000$-28,344,000$-24,993,000$-29,518,000$-27,754,000$-25,645,000
    EBITDA$-40,638,000$-29,083,000$-29,303,000$-24,214,000$-25,823,000$-35,625,000$-30,475,000$-33,407,000$-29,908,000$-32,077,000$-30,984,000$-29,683,000
    EBIT$-42,906,000$-30,670,000$-30,705,000$-25,567,000$-26,947,000$-36,359,000$-30,829,000$-33,797,000$-30,717,000$-32,764,000$-31,210,000$-29,261,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NKTX

    News

    Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX

    Monaco Asset Management SAM has acquired a new stake of 2.37 million shares in Nkarta, Inc. (NASDAQ:NKTX), valued at approximately $6.7 million, making it their 13th largest position and representing 3.32% of Nkarta. Despite Nkarta missing analyst expectations for its last quarterly earnings with a loss of $0.54 per share, institutional investors now own 80.54% of the company. Analyst sentiment remains a "Moderate Buy" with an average price target of $11.20, although some firms have lowered price objectives and earnings estimates due to projected continued losses.

    MarketBeat•8/17/26•
    Neutral

    Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen

    Wall Street Zen has downgraded Nkarta (NASDAQ:NKTX) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy" with an $11.20 target. Nkarta's shares opened at $2.33, near its 1-year low, and the company reported a quarterly loss of $0.54 per share, worse than estimates. Institutional investors hold a significant portion of the company's stock, and analysts project a full-year loss of $1.54 per share.

    MarketBeat•8/15/26•
    Somewhat-Bearish

    Stifel cuts Nkarta stock price target on updated model

    Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) from $11.00 to $10.00, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated model. The adjustment reflects ongoing patient enrollment progress in Nkarta's Ntrust-1/2 trials and upcoming preliminary data expected by year-end 2026. Despite the target cut, InvestingPro data suggests the stock may be undervalued, noting Nkarta's strong cash position but also its rapid cash burn, a common characteristic for clinical-stage biotech firms.

    Investing.com•8/15/26•
    Somewhat-Bearish

    Stifel cuts Nkarta stock price target on updated model By Investing.com

    Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $10 from $11, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated financial model. The adjustment comes after discussions with Nkarta's management regarding patient enrollment progress in its Ntrust-1/2 trials and anticipated preliminary data by the end of 2026. Despite the price target cut, InvestingPro data suggests Nkarta may be undervalued, although the biotech company is noted for rapidly burning through cash, a common trait for firms in clinical development.

    Investing.com Canada•8/14/26•
    Somewhat-Bearish

    Stifel cuts Nkarta stock price target on updated model

    Stifel lowered its price target on Nkarta Inc. (NASDAQ:NKTX) to $10.00 from $11.00, maintaining a Buy rating, following the company's Q2 2026 earnings and an updated model. The firm discussed patient enrollment progress in the Ntrust-1/2 trials and anticipates preliminary data by the end of 2026. Despite a strong balance sheet, Nkarta is rapidly burning cash, a common issue for biotechs in clinical development.

    Investing.com•8/14/26•
    Somewhat-Bearish

    Frequently Asked Questions About NKTX

    Does NKTX pay dividends?
    Nkarta Inc (NKTX) does not currently pay a regular dividend.
    What is NKTX's market cap?
    Nkarta Inc (NKTX) has a market capitalization of $194.10M with a current stock price of $2.71.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In